NCT07175220

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

A Multicenter, Open Label Phase II Clinical Study on the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination With Other Anti-tumor Treatments in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer

Conditions

• Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	SHR2554; SHR-A2102	SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days
DRUG	SHR2554; Adabelimumab	SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days
DRUG	SHR2554; SHR-1701	SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days

Timeline

• Start date: 2025-10-09
• Primary completion: 2028-10-01
• Completion: 2028-10-01
• First posted: 2025-09-16
• Last updated: 2025-11-18

Locations

1 site across 1 country: China